Summit Therapeutics INC

Summit Therapeutics announced updated overall survival results from its global Phase III HARMONi clinical trial, demonstrating consistent efficacy with ivonescimab plus chemotherapy.

Updated overall survival data from Akeso's Phase III HARMONi-2 trial for ivonescimab in advanced NSCLC shows a statistically significant benefit compared to pembrolizumab.

Summit Therapeutics' partner, Akeso Inc., announced statistically significant overall survival (OS) results from the Phase III HARMONi-2 study for ivonescimab in advanced non-small cell lung cancer.

Summit Therapeutics' partner, Akeso, Inc., announced positive topline results from the Phase III HARMONi-GI1 study evaluating ivonescimab plus chemotherapy for advanced biliary tract cancer, meeting primary and key secondary endpoints.

Summit Therapeutics announces the initiation of a global Phase II/III HARMONi-GU1 trial for ivonescimab in first-line bladder cancer, expanding its development program.

Summit Therapeutics Inc. has entered into a distribution agreement with J.P. Morgan Securities LLC to offer and sell up to $380 million of its common stock.

Summit Therapeutics reports on progress in ivonescimab clinical trials and financial performance for Q2 2026, highlighting ongoing development and need for future financing.

Summit Therapeutics reports Q1 2026 financial results, highlighting ongoing clinical development of ivonescimab and substantial doubt regarding its ability to continue as a going concern.

Summit Therapeutics reported a significantly wider net loss in Q3 2025, driven by increased R&D and administrative expenses, despite positive clinical trial updates for ivonescimab.

Summit Therapeutics reported a significantly increased net loss in Q2 2025, driven by substantial R&D and G&A expenses, despite positive Phase III ivonescimab data and recent capital raises.

Summit Therapeutics' Q1 2025 results reflect increased investment in the clinical development of ivonescimab, a novel bispecific antibody for oncology.

Summit Therapeutics reported its Q3 2024 financial results and provided updates on the clinical development of its lead candidate, ivonescimab, including the completion of enrollment in the HARMONi trial.

Summit Therapeutics' Biologics License Application for ivonescimab in EGFR-mutated NSCLC was accepted by the FDA, despite the primary analysis not achieving statistically significant overall survival.

Summit Therapeutics Inc. files its 10-K report, detailing financial results for 2024 and outlining progress in the clinical development of its lead candidate, ivonescimab.

Summit Therapeutics Inc.'s 10-K filing details its financial position, strategic shift to oncology, and ongoing development of ivonescimab.

Co-CEO Mahkam Zanganeh acquired 3.81 million shares of Summit Therapeutics common stock at $13.12 per share.

Co-CEO Robert W. Duggan increased his stake in Summit Therapeutics by purchasing 3.81 million shares at $13.12 per share.

Co-CEO Robert W. Duggan increased his stake in Summit Therapeutics through a purchase of 100,000 shares at $14.60 per share.

Co-CEO Mahkam Zanganeh acquired 100,000 shares of Summit Therapeutics common stock at $14.60 per share.

Summit Therapeutics COO and CFO Manmeet Singh Soni purchased 50,000 shares of common stock in open market transactions.

Summit Therapeutics Inc. granted 30,000 stock options to Chief Accounting Officer Bhaskar Anand with an exercise price of $18.83, vesting annually over four years.

Summit Therapeutics Inc. has issued its 2026 proxy statement detailing proposals for director elections, auditor ratification, executive compensation, and a stock incentive plan amendment.

Summit Therapeutics Inc. will hold its 2025 annual meeting of stockholders virtually on June 12, 2025, to vote on the election of directors, ratification of the independent accounting firm, and executive compensation.

Ujwala Mahatme, a Summit Therapeutics board member since July 2020, has resigned effective June 12, 2024, due to increasing professional commitments, and will not stand for re-election at the upcoming Annual Meeting.

Summit Therapeutics Inc. has scheduled its 2024 annual meeting of stockholders for June 14, 2024, to be held virtually, and has released its proxy statement outlining proposals for voting.